Carbonic anhydrase IX and renal cell carcinoma: Prognosis, response to systemic therapy, and future vaccine strategies

BJU International, Supplement

Volumn 101, Issue SUPPL.4, 2008, Pages 25-30

  Shuch, Brian ^a   Li, Zhenhua ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CARBONATE DEHYDRATASE IX; DENDRITIC CELL VACCINE; INTERLEUKIN 2; MONOCLONAL ANTIBODY G250; ANTINEOPLASTIC AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN;

BLADDER CARCINOMA; BRAIN CANCER; BREAST CANCER; CANCER GRADING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SARCOMA; SYSTEMIC THERAPY; TREATMENT RESPONSE; UTERINE CERVIX CANCER; ADJUVANT CHEMOTHERAPY; ENZYMOLOGY; KIDNEY TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEPHRECTOMY; PROGNOSIS;

EID: 44449143994     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Der CJ, Stanbridge EJ. A tumour-specific membrane phosphoprotein marker in human cell hybrids. Cell 1981; 26: 429-438
2. Pastorek J, Pastorekova S, Callebaut I et al. Cloning and characterization of MN, a human tumour-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994; 9: 2877-2888 (Pubitemid 24296762)
3. Liao SY, Brewer C, Zavada J et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 1994; 145: 598-609 (Pubitemid 24285967)
4. Opavsky R, Pastorekova S, Zelnik V et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996; 33: 480-487 (Pubitemid 26159864)
5. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 489-494 (Pubitemid 16006918)
6. Oosterwijk E, Ruiter DJ, Wakka JC et al. Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma. Am J Pathol 1986; 123: 301-309 (Pubitemid 16072530)
7. Grabmaier K, Vissers JL, De Weijert MC etal. Molecular cloning and immunogenicity of renal cell carcinomaassociated antigen G250. Int J Cancer 2000; 85: 865-870 (Pubitemid 30131479)
8. Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003; 89: 2-7 (Pubitemid 36897927)
9. Kim SJ, Rabbani ZN, Vollmer RT et al. Carbonic anhydrase IX in early-stage nonsmall cell lung cancer. Clin Cancer Res 2004; 10: 7925-7933 (Pubitemid 39587532)
10. Haapasalo JA, Nordfors KM, Hilvo M et al. Expression of carbonic anhydrase IX in astrocytic tumours predicts poor prognosis. Clin Cancer Res 2006; 12: 473-477 (Pubitemid 43166138)
11. Swinson DE, Jones JL, Richardson D et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumour hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003; 21: 473-482 (Pubitemid 46613490)
12. Loncaster JA, Harris AL, Davidson SE et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001 ; 61: 6394-6399
13. Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 2003; 89: 1290-1297 (Pubitemid 37363419)
14. Trastour C, Benizri E, Ettore F et al. HIF-1α and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007; 120: 1451-1458 (Pubitemid 46355379)
15. Generali D, Fox SB, Berruti A et al. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer 2006; 13: 921-930
16. Beasley NJ, Wykoff CC, Watson PH et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61: 5262-5267
17. Turner KJ, Crew JP, Wykoff CC et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 2002; 86: 1276-1282
18. Brizel DM, Scully SP, Harrelson JM et al. Tumour oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-943
19. Maseide K, Kandel RA, Bell RS et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004; 10: 4464-4471 (Pubitemid 38878890)
20. Bartosova M, Parkkila S, Pohlodek K et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 2002; 197: 314-321 (Pubitemid 34778301)
21. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Expression of hypoxiainducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001 ; 61: 7992-7998 (Pubitemid 33049392)
22. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumour hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiât Oncol Biol Phys 1997; 38: 285-289 (Pubitemid 27318643)
23. Koukourakis MI. Giatromanolaki A, Sivridis E et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7: 3399-3403 (Pubitemid 33069972)
24. Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumourassociated carbonic anhydrases. Cancer Res 2000; 60: 7075-7083
25. Chia SK, Wykoff CC, Watson PH et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001; 19: 3660-3668
26. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997; 57: 2827-2831 (Pubitemid 27315020)
27. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-811 (Pubitemid 36182618)
28. Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int 2005; 96: 281-285 (Pubitemid 41097666)
29. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007; 100: 556-560 (Pubitemid 47205465)
30. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275
31. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000; 19: 6297-6305
32. Kondo K, Yao M, Yoshida M et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002; 34: 58-68 (Pubitemid 34260597)
33. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90 (Pubitemid 24232386)
34. Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol; 171: 2461-2466
35. Patard J, Fergelot P, Karakiewicz PI et al. CAIX and VHL status define two types of clear cell renal cell carcinoma: low CAIX expression and absence of VHL gene mutation are associated with tumour aggressiveness and poor survival. 2008 (in press)
36. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma J Urol 2001; 166: 63-67
37. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-1657 (Pubitemid 32230864)
38. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumour stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-2400
39. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 1460-1468
40. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540 (Pubitemid 29368255)
41. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559-4566 (Pubitemid 35402959)
42. Negrier S. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 2005; 23 (Suppl.): 4511 (Abstract)
43. Stephenson AJ, Smith A, Kattan MW et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005; 104: 290-298 (Pubitemid 40993255)
44. Klatte T, Seligson DB, Pantuck AJ et al. Molecular tumour profiling improved risk assessment and prognostication of patients with non-metastatic clear cell renal cell carcinoma. AUA Annual Meeting, 2007: 491
45. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281 (Pubitemid 46849157)
46. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696
47. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997; 158: 1691-1695 (Pubitemid 27433133)
48. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134 (Pubitemid 46089673)
49. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J Clin Oncol 2002; 20: 2376-2381 (Pubitemid 34441667)
50. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-3721 (Pubitemid 40685588)
51. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852 (Pubitemid 37485197)
52. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005; 174: 466-472 (Pubitemid 40981575)
53. Leibovich BC, Han KR, Bui MH et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98: 2566-2575 (Pubitemid 37509519)
54. Tso CL, Zisman A, Pantuck A et al. Induction of G250-targeted and T-cellmediated antitumour activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 2001; 61: 7925-7933 (Pubitemid 33049383)
55. Mukouyama H, Janzen NK, Hernandez JM et al. Generation of kidney cancerspecific antitumour immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res 2004; 10: 1421-9